Accéder au contenu
Merck
Toutes les photos(1)

Key Documents

PHR1620

Supelco

Fluvastatin sodium

Pharmaceutical Secondary Standard; Certified Reference Material

Synonyme(s) :

(3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid monosodium salt

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme


About This Item

Formule empirique (notation de Hill):
C24H25FNNaO4
Numéro CAS:
Poids moléculaire :
433.45
Numéro MDL:
Code UNSPSC :
41116107
ID de substance PubChem :
Nomenclature NACRES :
NA.24

Qualité

certified reference material
pharmaceutical secondary standard

Niveau de qualité

Agence

traceable to Ph. Eur. Y0001082
traceable to USP 1285931

Famille d'API

fluvastatin

CofA (certificat d'analyse)

current certificate can be downloaded

Conditionnement

ampule of 1 × 1 g

Technique(s)

HPLC: suitable
gas chromatography (GC): suitable

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-30°C

Chaîne SMILES 

[Na+].CC(C)n1c(\C=C\[C@H](O)C[C@H](O)CC([O-])=O)c(-c2ccc(F)cc2)c3ccccc13

InChI

1S/C24H26FNO4.Na/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);/q;+1/p-1/b12-11+;/t18-,19-;/m0./s1

Clé InChI

ZGGHKIMDNBDHJB-RPQBTBOMSA-M

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

Fluvastatin sodium is a lipid-lowering drug that belongs to the group of compounds known as statins. It acts by inhibiting the enzyme HMG-CoA reductase that plays a key role in the cholesterol production. It is generally used to reduce plasma cholesterol levels and prevent cardiovascular disease.
Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.

Application

Fluvastatin sodium may be used as a reference standard for the determination of the analyte in bulk drug and pharmaceutical formulations by high performance liquid chromatography.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Note de bas de page

To see an example of a Certificate of Analysis for this material enter LRAA5290 in the slot below. This is an example certificate only and may not be the lot that you receive.

Code de la classe de stockage

11 - Combustible Solids

Classe de danger pour l'eau (WGK)

WGK 3

Point d'éclair (°F)

Not applicable

Point d'éclair (°C)

Not applicable


Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Vous ne trouvez pas la bonne version ?

Si vous avez besoin d'une version particulière, vous pouvez rechercher un certificat spécifique par le numéro de lot.

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Les clients ont également consulté

Slide 1 of 1

1 of 1

The role of statin drugs in combating cardiovascular diseases-A review
Pichandi S, et al
International journal of current science research, 1(2), 47-56 (2011)
Fluvastatin Sodium
USP42/NF37: United States Pharmacopeia and National Formulary
United States Pharmacopeia/National Formulary, 43(5), 1972-1972 (2019)
Determination of Fluvastatin Sodium Extended-release Tablets by HPLC
Zhang S, et al.
China Pharmacy, 42(34), 1784-1804 (2007)
Development and validation of stability-indicating HPLC methods for quantitative determination of pravastatin, fluvastatin, atorvastatin, and rosuvastatin in pharmaceuticals
Gomes FP, et al.
Analytical Letters, 42(12), 1784-1804 (2009)
Masao Nishiya et al.
Anti-cancer drugs, 30(5), 451-457 (2019-03-29)
Although vemurafenib has been shown to improve the overall survival of patients with metastatic melanoma harboring the BRAF V600E mutation, its efficacy is often hampered by drug resistance acquired within a relatively short period through several distinct mechanisms. In the

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique